SCHEMBL7172994

SCHEMBL7172994

O=[N+]([O-])c1ccc2cc(-c3ccccc3)cn2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ RCE1 Q9Y256 1/20 0.42
▸ KMT2A Q03164 4/20 0.41
▸ CRHBP P24387 3/20 0.41
▸ CRHR2 Q13324 3/20 0.41
▸ CYP19A1 P11511 2/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ RAB9A P51151 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ NPBWR1 P48145 1/20 0.40
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852148 0.79 MAPT (0.54) POLBMAPK1LMNAALDH1A1RCE1
SCHEMBL7171370 0.75 ACHE (0.48) POLBLMNAALDH1A1KMT2AMEN1
Biphenyl SCHEMBL27380379 0.74 ALDH1A1 (0.75) POLBMAPK1LMNAALDH1A1KMT2A
SCHEMBL7167655 0.74 CRHBP (0.44) MAPK1LMNAALDH1A1KMT2ACRHBP
SCHEMBL25187033 0.72 MAPK1 (0.74) POLBMAPK1LMNAALDH1A1KMT2A
Biphenyl SCHEMBL27846163 0.72 ALDH1A1 (0.71) POLBMAPK1LMNAALDH1A1RCE1
SCHEMBL167524 0.72 MAPK1 (0.74) POLBMAPK1LMNAALDH1A1KMT2A
SCHEMBL27444638 0.71 MAPK1 (0.67) POLBMAPK1LMNAALDH1A1RCE1
SCHEMBL28375748 0.70 MAPK1 (0.71) POLBMAPK1LMNAALDH1A1RCE1
Ammonia Solution, Strong SCHEMBL9570816 0.70 MAPK1 (0.71) POLBMAPK1LMNAALDH1A1RCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6572664-B2 Oxidation dyeing of keratin fibers L'OREAL S.A. (FR) 2003-06-03 — — US claimed
US-20020170121-A9 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same L'OREAL S.A. (FR) 2002-11-21 — — US claimed
US-20020002749-A1 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same BRETON PHILIPPE (FR) 2002-01-10 — — US claimed
EP-1129691-A2 Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same L'OREAL (FR) 2001-09-05 — — EP claimed
US-6572664-B2 Oxidation dyeing of keratin fibers L'OREAL S.A. (FR) 2003-06-03 — — US disclosed
US-20020170121-A9 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same L'OREAL S.A. (FR) 2002-11-21 — — US disclosed
US-20020002749-A1 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same BRETON PHILIPPE (FR) 2002-01-10 — — US disclosed
EP-1129691-A2 Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same L'OREAL (FR) 2001-09-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002749-A1 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same KRT18, INMT, IDO1 POLB 833/4885MAPK1 2493/4885LMNA 1125/4885
US-20020170121-A9 Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same KRT18, INMT, IDO1 POLB 833/4885MAPK1 2493/4885LMNA 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback